Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
Cash Flow Statement
8 Sheets · From 2022 to 2015Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Cash Flow (OCF) | 154.00 | -86.00 | -88.00 | -68.00 | -13.00 | -55.00 | -102.00 | -117.00 | |
| Operating Cash (Net) | 154.00 | -86.00 | -88.00 | -68.00 | -13.00 | -55.00 | -102.00 | -117.00 | |
| Accounts Receivable | -1.00 | 3.00 | - - | -11.00 | 11.00 | - - | -9.00 | 8.00 | |
| Accounts Payable | 1.00 | -2.00 | -1.00 | - - | - - | - - | 4.00 | 1.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Change | - - | - - | -1.00 | -10.00 | - - | -8.00 | -5.00 | 19.00 | |
| Other WC | - - | - - | 1.00 | 10.00 | - - | - - | - - | 8.00 | |
| Investing Activities | |||||||||
| Used Cash (Net) | -297.00 | -32.00 | 88.00 | 39.00 | - - | 109.00 | -112.00 | -99.00 | |
| Capital Expenditure | -2.00 | -23.00 | -5.00 | -2.00 | - - | - - | -1.00 | -1.00 | |
| Purchases of Investments | -359.00 | -359.00 | -260.00 | -226.00 | -283.00 | -16.00 | -232.00 | -299.00 | |
| Sale/Maturity of Investment | 77.00 | 351.00 | 354.00 | 268.00 | 282.00 | 52.00 | 121.00 | 200.00 | |
| Property, Plant, Equipment (P&PE) | -2.00 | -23.00 | -5.00 | -2.00 | - - | - - | -1.00 | -1.00 | |
| Acquisitions (Net) | -14.00 | - - | - - | - - | - - | - - | - - | 99.00 | |
| Other Investing Activities | - - | - - | - - | - - | - - | 74.00 | - - | -99.00 | |
| Financing Activities | |||||||||
| Used Cash (Net) | -174.00 | -43.00 | -82.00 | -1.00 | -25.00 | -124.00 | -209.00 | -151.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Issued | 150.00 | 36.00 | 78.00 | - - | - - | 109.00 | 206.00 | 145.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 23.00 | 6.00 | 3.00 | -1.00 | 25.00 | 14.00 | 3.00 | 5.00 | |
| Cash Balances | |||||||||
| Begin of Period | 119.00 | 150.00 | 74.00 | 158.00 | 126.00 | 11.00 | 189.00 | 183.00 | |
| End of Period | 150.00 | 74.00 | 157.00 | 126.00 | 11.00 | 189.00 | 183.00 | 117.00 | |
| Change | 31.00 | -75.00 | 82.00 | -31.00 | -115.00 | 178.00 | -5.00 | -66.00 | |
| Non-Cash Balances | |||||||||
| Depreciation and Amortization | - - | 2.00 | 3.00 | 4.00 | - - | 1.00 | 4.00 | 5.00 | |
| Stock Based Compensation | 8.00 | 15.00 | 16.00 | 17.00 | - - | 3.00 | 12.00 | 20.00 | |
| Other | 184.00 | -5.00 | -22.00 | 14.00 | 35.00 | 31.00 | -13.00 | 21.00 | |
| Highlighted metrics | |||||||||
| Free Cash Flow (FCF) | 152.00 | -109.00 | -94.00 | -71.00 | -14.00 | -56.00 | -104.00 | -119.00 | |
| Cash Conversion Cycle (CCC) | -20,834.00 | -1,458.00 | -729.00 | -619.00 | -2,569.00 | -3,339.00 | -1,785.00 | -2,001.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - |